

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of:

Lam, et al.

**Confirmation No.: 1161** 

**Application No.: 09/802,709** 

Group Art Unit: 1614

JUL 2 0 2004

Filing Date: March 8, 2001

Examiner: Z. Fay

**TECH CENTER 1600/2900** 

For: Methods And Devices For Providing Drug Therapy

EXPRESS MAIL LABEL NO: EL 998515342

DATE OF DEPOSIT: July 14, 2004

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

07/16/2004 HLE333 00000087 09802709

01 FC:1806

180.00 OP

## DOCKET NO.: ALZA-0023(ARC2865N1)- 2 -

	before the mailing date of a first Office Action after the filing of request for
	continued examination under § 1.114, no additional fee is required.
$\boxtimes$	In accordance with § 1.97(c), this Information Disclosure Statement is being
	filed after the period set forth in § 1.97(b) above but before the mailing date of
	either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or
	before an action that otherwise closes prosecution in the application, therefore:
	Certification in Accordance with § 1.97(e) is attached;
	or
	$\square$ The fee of \$\frac{\$180.00}{}\$ as set forth in \\$ 1.17(p) is attached.
	In accordance with § 1.97(d), this Information Disclosure Statement is being
	filed after the mailing date of either a Final Action under § 1.113 or a Notice
	of Allowance under § 1.311 but before, or simultaneously with, the payment
	of the Issue Fee, therefore included are: Certification in Accordance with §
	1.97(e); and the submission fee of <b>\$180.00</b> as set forth in § 1.17(p).
$\boxtimes$	Copies of each of the references listed on the attached Form PTO-1449 are
	enclosed herewith.
	Copies of references listed on the attached Form PTO-1449 are enclosed
	herewith EXCEPT THAT:
	Copies of references listed on the attached Form PTO 1449 are not required to
	be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR §
	1.98(a)(2)(i).
ı	
	In accordance with § 1.98(d), copies of the following references listed
	on the attached Form PTO-1449 are not enclosed herewith because

DOCKET NO.: ALZA-0023(ARC2865N1)- 3 - PATENT

they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C.§ 120 have been made in the instant application:

Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No., filed

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

The relevance of those listed references which are not in the English language is as follows:

The relevance of the Non-English language citation is submitted on the basis of the accompanying copy of the EPO search report that is in the English language.


Date: July 14, 2004

Joseph Lucci

Registration No. 33,307

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2004 WW



© 2004 WW